IVEVF

Inventiva S.A.

Price Chart

Latest Quote

$3.59

+0.00 (+0.00%)

Current Price

Previous Close	$3.59
Open	$3.59
Day High	$3.59
Day Low	$3.59
Volume	100

Fetched: 2026-06-25T23:12:01

Stock Information

Note: Financial values converted from EUR to USD

Shares Outstanding	236.22M
Total Debt	$262.52M
Cash Equivalents	$113.52M
Revenue	$7.69M
Net Income	$-402.66M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$848.03M
EPS (TTM)	$-2.17
Exchange	PNK

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$876.72M
Sales	$7.69M
Income	$-402.66M
Book/sh	$-0.17
Cash/sh	$0.42
Employees	69

Financial Ratios

Quick Ratio	1.41
Current Ratio	3.16

Returns & Margins

ROA	-45.08%
Gross Margin	99.68%
Operating Margin	-6710.69%

Ownership

Insider Ownership	12.67%
Institutional Ownership	49.68%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.74
P/S	125.43
P/B	-21.06

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$4.89
SMA50	$5.19
SMA200	$4.38
ATR	0.1243

Shares Float	154.23M
Volatility	0.88

Performance History

Week	-32.65%
Month	-32.65%
Quarter	-19.14%
6 Months	-19.14%
YTD	-19.14%
Year	+57.46%
3 Years	-9.11%
5 Years	-66.88%
10 Years	+49.58%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$3.59	0
2026-06-23	$3.59	0
2026-06-22	$3.59	0
2026-06-18	$3.59	0
2026-06-17	$3.59	100
2026-06-16	$5.33	0
2026-06-15	$5.33	0
2026-06-12	$5.33	0
2026-06-11	$5.33	0
2026-06-10	$5.33	0
2026-06-09	$5.33	0
2026-06-08	$5.33	0
2026-06-05	$5.33	0
2026-06-04	$5.33	0
2026-06-03	$5.33	0
2026-06-02	$5.33	0
2026-06-01	$5.33	0
2026-05-29	$5.33	0
2026-05-28	$5.33	0
2026-05-27	$5.33	0
2026-05-26	$5.33	0

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

📰 Latest News

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround

Zacks • 2026-06-11T13:35:02Z

Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses

Simply Wall St. • 2026-05-21T06:11:30Z

How The Inventiva (ENXTPA:IVA) Story Is Shifting As Analyst Views Grow More Divided

Simply Wall St. • 2026-05-20T00:21:23Z

Inventiva Builds Up Leadership Team Ahead of Potential Commercialization

Exec Edge • 2026-04-22T22:03:19Z

How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions

Simply Wall St. • 2026-04-07T04:32:40Z

Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial ...

GuruFocus.com • 2026-04-02T01:01:02Z

Inventiva Q4 Earnings Call Highlights

MarketBeat • 2026-03-31T14:10:34Z

Assessing Inventiva (ENXTPA:IVA) Valuation After A Strong 12‑Month Rebound In Shareholder Returns

Simply Wall St. • 2026-02-28T23:13:56Z

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?

Zacks • 2026-02-27T14:55:03Z

Inventiva CEO: Phase 3 Lanifibranor MASH Trial Fully Enrolled, Top-Line Data Due in H2

MarketBeat • 2026-02-14T05:02:10Z

Period:

Income Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue
Total Revenue	$9,198,000	$17,477,000	$12,179,000	$4,194,000
Operating Revenue	$9,198,000	$17,477,000	$12,179,000	$4,194,000
Expenses
Interest Expense	$12,178,000	$5,178,000	$707,000	$138,000
Total Expenses	$103,187,000	$120,142,000	$69,036,000	$55,368,000
Other Income Expense	$-78,843,000	$-2,920,000	$2,927,000	$1,985,000
Net Non Operating Interest Income Expense	$-11,069,000	$-4,233,000	$-364,000	$-86,000
Total Other Finance Cost	$34,000	$46,000	$47,000	$5,000
Interest Expense Non Operating	$12,178,000	$5,178,000	$707,000	$138,000
Operating Expense	$103,187,000	$120,142,000	$69,036,000	$55,368,000
Other Operating Expenses	$-5,486,000	$-5,686,000	$-6,929,000	$-6,495,000
Selling And Marketing Expense	$1,686,000	$1,755,000	$2,365,000	$151,000
General And Administrative Expense	$15,413,000	$13,852,000	$12,911,000	$11,193,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Net Interest Income	$-11,069,000	$-4,233,000	$-364,000	$-86,000
Interest Income	$1,143,000	$991,000	$390,000	$57,000
Normalized Income	$-125,314,500	$-109,747,250	$-57,199,244	$-51,093,975
Net Income From Continuing And Discontinued Operation	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Total Operating Income As Reported	$-97,558,000	$-102,709,000	$-57,110,000	$-52,114,000
Net Income Common Stockholders	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Net Income	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Net Income Including Noncontrolling Interests	$-184,214,000	$-110,425,000	$-54,274,000	$-49,639,000
Net Income Continuous Operations	$-184,214,000	$-110,425,000	$-54,274,000	$-49,639,000
Pretax Income	$-183,901,000	$-109,818,000	$-54,294,000	$-49,275,000
Special Income Charges	$-3,729,000	$-44,000	$-130,000	$-943,000
Earnings From Equity Interest	$-313,000	$-2,015,000	$0	$0
Interest Income Non Operating	$1,143,000	$991,000	$390,000	$57,000
Operating Income	$-93,989,000	$-102,665,000	$-56,857,000	$-51,174,000
Depreciation Amortization Depletion Income Statement	$694,000	$209,000	$220,000	$176,000
Depreciation And Amortization In Income Statement	$694,000	$209,000	$220,000	$176,000
Per Share
Diluted EPS	$-3.08	$-2.43	$-1.31	$-1.27
Basic EPS	$-3.08	$-2.43	$-1.31	$-1.27
Other
Tax Effect Of Unusual Items	$-19,632,500	$-226,250	$1,756	$526,025
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-87,995,000	$-101,136,000	$-54,816,000	$-50,946,000
Total Unusual Items	$-78,530,000	$-905,000	$2,927,000	$1,985,000
Total Unusual Items Excluding Goodwill	$-78,530,000	$-905,000	$2,927,000	$1,985,000
Reconciled Depreciation	$5,198,000	$2,599,000	$1,698,000	$-1,288,000
EBITDA (Bullshit earnings)	$-166,525,000	$-102,041,000	$-51,889,000	$-48,961,000
EBIT	$-171,723,000	$-104,640,000	$-53,587,000	$-49,137,000
Diluted Average Shares	$59,778,701	$45,351,799	$41,449,732	$39,168,152
Basic Average Shares	$59,778,701	$45,351,799	$41,449,732	$39,168,152
Diluted NI Availto Com Stockholders	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Tax Provision	$313,000	$607,000	$-20,000	$364,000
Gain On Sale Of Ppe	$-10,000	$0	$-9,000	$9,000
Write Off	$372,000	$0	$0	$0
Impairment Of Capital Assets	$1,787,000	$0	$0	$0
Restructuring And Mergern Acquisition	$1,560,000	$44,000	$121,000	$952,000
Gain On Sale Of Security	$-74,801,000	$-861,000	$3,057,000	$2,928,000
Research And Development	$90,880,000	$110,012,000	$60,469,000	$48,452,000
Selling General And Administration	$17,099,000	$15,607,000	$15,276,000	$11,344,000
Other Gand A	$9,373,000	$8,885,000	$8,728,000	$7,424,000
Salaries And Wages	$6,040,000	$4,967,000	$4,183,000	$3,769,000
Other Taxes	-	$0	$0	$2,224,000
Provision For Doubtful Accounts	-	$0	$0	$-333,000

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Net Tangible Assets	$-106,694,000	$-32,573,000	$44,908,000	$88,097,000
Total Assets	$118,967,000	$69,561,000	$116,004,000	$121,985,000
Total Non Current Assets	$7,456,000	$21,374,000	$9,622,000	$6,410,000
Non Current Prepaid Assets	$1,047,000	$10,055,000	$1,603,000	$2,442,000
Non Current Deferred Assets	$217,000	$225,000	$0	$0
Non Current Deferred Taxes Assets	$217,000	$225,000	$0	$0
Goodwill And Other Intangible Assets	$48,000	$542,000	$568,000	$770,000
Other Intangible Assets	$48,000	$542,000	$568,000	$770,000
Current Assets	$111,511,000	$48,190,000	$106,384,000	$115,578,000
Other Current Assets	$349,000	$422,000	$282,000	$763,000
Prepaid Assets	$2,442,000	$4,656,000	$8,601,000	$7,454,000
Inventory	$0	$417,000	$373,000	$392,000
Receivables	$12,157,000	$15,707,000	$9,343,000	$11,587,000
Other Receivables	$1,630,000	$1,482,000	$279,000	$386,000
Taxes Receivable	$9,996,000	$10,418,000	$9,064,000	$7,201,000
Accounts Receivable	$531,000	$3,807,000	$0	$4,000,000
Cash Cash Equivalents And Short Term Investments	$96,563,000	$26,988,000	$87,785,000	$95,382,000
Cash And Cash Equivalents	$96,563,000	$26,918,000	$86,737,000	$86,553,000
Cash Equivalents	$70,655,000	$17,933,000	$16,798,000	$42,900,000
Cash Financial	$25,908,000	$8,985,000	$69,939,000	$43,653,000
Investmentin Financial Assets	-	$9,000,000	$700,000	$1,745,000
Non Current Accounts Receivable	-	-	$65,000	-
Hedging Assets Current	-	-	$0	$0
Other Non Current Assets	-	-	-	$-2,000
Debt
Total Debt	$54,329,000	$37,489,000	$34,515,000	$10,120,000
Long Term Debt And Capital Lease Obligation	$48,461,000	$32,181,000	$28,664,000	$8,838,000
Long Term Debt	$46,326,000	$27,914,000	$25,431,000	$8,746,000
Current Debt And Capital Lease Obligation	$5,868,000	$5,308,000	$5,851,000	$1,282,000
Current Debt	$3,348,000	$3,010,000	$4,574,000	$1,244,000
Other Current Borrowings	$3,348,000	$3,010,000	$4,574,000	$1,244,000
Net Debt	-	$4,006,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$225,613,000	$101,592,000	$70,528,000	$33,118,000
Total Non Current Liabilities Net Minority Interest	$104,882,000	$51,434,000	$39,827,000	$10,265,000
Other Non Current Liabilities	$30,237,000	$7,359,000	$-2,000	$-2,000
Derivative Product Liabilities	$24,315,000	$10,265,000	$9,876,000	$0
Non Current Deferred Liabilities	$107,000	$70,000	$55,000	$0
Current Liabilities	$120,731,000	$50,158,000	$30,701,000	$22,853,000
Other Current Liabilities	$73,401,000	-	$-1,000	$1,000
Current Deferred Liabilities	$0	$6,000	$6,000	$180,000
Payables And Accrued Expenses	$41,462,000	$44,844,000	$24,845,000	$21,390,000
Payables	$39,721,000	$43,304,000	$23,505,000	$20,156,000
Other Payable	$2,935,000	$1,892,000	$1,878,000	$4,497,000
Total Tax Payable	$3,924,000	$3,733,000	$2,268,000	$1,057,000
Accounts Payable	$32,862,000	$37,679,000	$19,359,000	$14,602,000
Current Deferred Taxes Liabilities	-	$0	$0	$180,000
Equity
Common Stock Equity	$-106,646,000	$-32,031,000	$45,476,000	$88,867,000
Total Equity Gross Minority Interest	$-106,646,000	$-32,031,000	$45,476,000	$88,867,000
Stockholders Equity	$-106,646,000	$-32,031,000	$45,476,000	$88,867,000
Gains Losses Not Affecting Retained Earnings	$-172,551,000	$-123,988,000	$-74,557,000	$-26,979,000
Other Equity Adjustments	$-173,151,000	$-124,584,000	$-74,286,000	$-26,815,000
Retained Earnings	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Long Term Equity Investment	$1,139,000	$1,425,000	$0	$0
Other
Treasury Shares Number	$120,522	$106,115	-	-
Ordinary Shares Number	$95,662,391	$52,115,807	$42,134,169	$40,873,551
Share Issued	$95,782,913	$52,221,922	$42,134,169	$40,873,551
Tangible Book Value	$-106,694,000	$-32,573,000	$44,908,000	$88,097,000
Invested Capital	$-56,972,000	$-1,107,000	$75,481,000	$98,857,000
Working Capital	$-9,220,000	$-1,968,000	$75,683,000	$92,725,000
Capital Lease Obligations	$4,655,000	$6,565,000	$4,510,000	$130,000
Total Capitalization	$-60,320,000	$-4,117,000	$70,907,000	$97,613,000
Foreign Currency Translation Adjustments	$600,000	$596,000	$-271,000	$-164,000
Additional Paid In Capital	$249,160,000	$201,862,000	$173,886,000	$165,072,000
Capital Stock	$957,000	$521,000	$421,000	$409,000
Common Stock	$957,000	$521,000	$421,000	$409,000
Employee Benefits	$1,762,000	$1,559,000	$1,234,000	$1,429,000
Non Current Pension And Other Postretirement Benefit Plans	$1,762,000	$1,559,000	$1,234,000	$1,429,000
Non Current Deferred Revenue	$107,000	$70,000	$55,000	$0
Long Term Capital Lease Obligation	$2,135,000	$4,267,000	$3,233,000	$92,000
Current Deferred Revenue	$0	$6,000	$6,000	$0
Current Capital Lease Obligation	$2,520,000	$2,298,000	$1,277,000	$38,000
Current Accrued Expenses	$1,741,000	$1,540,000	$1,340,000	$1,234,000
Investments And Advances	$1,139,000	$1,425,000	$0	$0
Net PPE	$5,005,000	$9,127,000	$7,386,000	$3,198,000
Accumulated Depreciation	$-15,193,000	$-10,713,000	$-8,556,000	$-7,123,000
Gross PPE	$20,198,000	$19,840,000	$15,942,000	$10,321,000
Construction In Progress	$20,000	$115,000	$65,000	$59,000
Other Properties	$10,717,000	$10,479,000	$6,778,000	$1,565,000
Machinery Furniture Equipment	$5,819,000	$5,604,000	$5,457,000	$5,118,000
Buildings And Improvements	$3,470,000	$3,470,000	$3,470,000	$3,407,000
Land And Improvements	$172,000	$172,000	$172,000	$172,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$0	$70,000	$1,048,000	$8,829,000
Available For Sale Securities	-	$9,000,000	$700,000	$1,745,000
Other Inventories	-	$417,000	$373,000	$392,000

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow
Free Cash Flow	$-86,261,000	$-82,154,000	$-45,489,000	$-48,163,000
Operating Activities
Operating Cash Flow	$-85,928,000	$-81,614,000	$-44,928,000	$-47,629,000
Cash Flow From Continuing Operating Activities	$-85,927,000	$-81,614,000	$-44,927,000	$-47,628,000
Operating Gains Losses	$-518,000	$2,312,000	$343,000	$-5,198,000
Investing Activities
Capital Expenditure	$-333,000	$-540,000	$-561,000	$-534,000
Investing Cash Flow	$8,745,000	$-7,731,000	$8,868,000	$-1,793,000
Cash Flow From Continuing Investing Activities	$8,745,000	$-7,731,000	$8,867,000	$-1,794,000
Net Other Investing Changes	-	-	$1,000	$1,000
Financing Activities
Issuance Of Capital Stock	$57,338,000	$30,589,000	$8,827,000	$25,475,000
Financing Cash Flow	$145,592,000	$29,081,000	$37,268,000	$25,447,000
Cash Flow From Continuing Financing Activities	$145,592,000	$29,081,000	$37,268,000	$25,447,000
Net Other Financing Charges	$10,096,000	$2,589,000	$30,209,000	-
Net Common Stock Issuance	$57,338,000	$30,589,000	$8,827,000	$25,475,000
Common Stock Issuance	$57,338,000	$30,589,000	$8,827,000	$25,475,000
Other
Repayment Of Debt	$-4,992,000	$-4,097,000	$-1,768,000	$-28,000
Issuance Of Debt	$24,916,000	$0	$30,209,000	$0
End Cash Position	$96,564,000	$26,918,000	$86,736,000	$86,553,000
Beginning Cash Position	$26,918,000	$86,736,000	$86,553,000	$105,687,000
Effect Of Exchange Rate Changes	$1,237,000	$445,000	$-1,025,000	$4,841,000
Changes In Cash	$68,409,000	$-60,263,000	$1,208,000	$-23,975,000
Proceeds From Stock Option Exercised	$58,234,000	$0	$0	-
Net Issuance Payments Of Debt	$19,924,000	$-4,097,000	$28,441,000	$-28,000
Net Long Term Debt Issuance	$19,924,000	$-4,097,000	$28,441,000	$-28,000
Long Term Debt Payments	$-4,992,000	$-4,097,000	$-1,768,000	$-28,000
Long Term Debt Issuance	$24,916,000	$0	$30,209,000	$0
Net Investment Purchase And Sale	$9,078,000	$-7,322,000	$9,387,000	$-1,349,000
Sale Of Investment	$9,078,000	$978,000	$9,388,000	-
Net PPE Purchase And Sale	$-333,000	$-409,000	$-520,000	$-445,000
Sale Of PPE	$0	$131,000	$41,000	$89,000
Purchase Of PPE	$-333,000	$-540,000	$-561,000	$-534,000
Taxes Refund Paid	$5,333,000	$5,220,000	$3,553,000	$7,957,000
Change In Working Capital	$1,679,000	$17,307,000	$5,713,000	$979,000
Change In Other Working Capital	$1,794,000	$3,190,000	$-1,685,000	$-1,231,000
Change In Payables And Accrued Expense	$-3,338,000	$20,002,000	$3,535,000	$7,599,000
Change In Payable	$-3,338,000	$20,002,000	$3,535,000	$7,599,000
Change In Inventory	$417,000	$-44,000	$19,000	$-72,000
Change In Receivables	$2,806,000	$-5,841,000	$3,844,000	$-5,317,000
Other Non Cash Items	$87,812,000	$2,146,000	$1,082,000	$737,000
Stock Based Compensation	$3,580,000	$3,969,000	$2,218,000	$2,089,000
Deferred Tax	$-4,800,000	$-4,741,000	$-5,261,000	$-3,270,000
Deferred Income Tax	$-4,800,000	$-4,741,000	$-5,261,000	$-3,270,000
Depreciation Amortization Depletion	$5,198,000	$2,599,000	$1,698,000	$-1,288,000
Depreciation And Amortization	$5,198,000	$2,599,000	$1,698,000	$-1,288,000
Depreciation	$5,198,000	$2,599,000	$1,698,000	$-1,288,000
Earnings Losses From Equity Investments	$152,000	$2,015,000	$0	$0
Net Foreign Currency Exchange Gain Loss	$-1,126,000	$297,000	$343,000	$-5,198,000
Gain Loss On Sale Of PPE	$456,000	$0	$0	-
Net Income From Continuing Operations	$-184,212,000	$-110,426,000	$-54,274,000	$-49,635,000
Purchase Of Investment	-	$-8,300,000	$-1,000	$-1,349,000

Fetched: 2026-02-02